Current systemic treatment for advanced stage hormone dependent breast cancer

Breast cancer is the leading cause of death in Chilean women. Since most of these tumors are estrogen -dependent, estrogen deprivation has historically been a relevant part of breast cancer treatments. However, the combination of endocrine treatment with targeted therapies has demonstrated better efficacy, improving overall survival of advanced estrogen-dependent breast cancer patients, compared to anti-estrogenic therapy alone. In recent decades, novel systemic therapies based on immunoconjugates, along with the discovery of low human epidermal growth factor receptor type 2 estrogen-dependent breast cancers (HER2-low), have expanded the available options for patients that display endocrine resistance. Herein, we deliver a brief review that summarizes novel systemic treatment options for estrogen-dependent advanced breast cancer patients.